|
Market Report
|
Acute Coronary Syndromes Fresh look at ACS in Europe, what is the real picture
The face of ACS is changing. The ageing population and pressure of growing risk factors have made a significant impact on the management strategies in ACS. This report unveils the true picture through in-depth analysis of data on over 21,000 ACS patient records in the 5 major European pharmaceutical markets (5EU; France, Germany, Italy, Spain and the UK).
|
|
Read more...
|
|
|
Market Report
|
Urinary Incontinence - Lifecycle management strategies retain mid-term market growth
The UI market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006. Lifecycle management strategies, novel formulations and follow-on products will drive the majority of this growth, with key brands expected to be Pfizer's Detrol LA (tolterodine) and Toviaz (fesoterodine), GSK's Vesicare (solifenacin), and Novartis' Enablex (darifenacin).
|
|
Read more...
|
|
|
Market Report
|
Autoimmune Overview - Market continues to prosper
The autoimmune disease market will be rapidly growing due to a high number of competitive brands currently on the market and a full pipeline. Company strategies include expanding the treatment algorithm by pursuing approval for 'early' disease stages, launching easy-to-use devices to make up for downsides of injectable drugs, and developing fully human monoclonal antibodies as follow-on products.
|
|
Read more...
|
|
|
Market Report
|
Benchmarking key countries Brazil, Russia, India, China and Turkey
With dwindling growth rates observed in the major developed markets many pharmaceutical companies are turning towards emerging market countries in order to sustain their revenue growth. While some countries, with double digit growth rates present tremendous opportunities, there are also many obstacles that need to be overcome.
|
|
Read more...
|
|
|
Market Report
|
Reaching Doctors and Patients Through New Digital Media
Existing sales and marketing models are considered unsustainable. Pharma has been slow to adapt and take advantage of the marketing opportunities offered by the internet. Meanwhile customers are increasingly using the web to source information. Pharma needs to evolve and engage with their customers online, or risk being left behind.
|
|
Read more...
|
|
|
Market Report
|
The CNS Market Outlook to 2011
Psychiatric and neurological disorders constitute as much as 35% of the disease burden in the seven major pharmaceutical markets, representing continuing opportunities for pharma companies in the CNS market.
|
|
Read more...
|
|
|
Market Report
|
Future Growth Opportunities in Generics: Impact of consolidation on market and competitive dynamics
The number of commercially lucrative drugs coming off patent has catalyzed the growth of the generics industry, creating significant profit opportunities for generics manufacturers. However, this market faces a considerable number of threats, with bulk manufacturers from developing countries becoming internationally competitive and the aggressive actions of branded pharmaceutical marketers in protecting their patent and market position resulting in ramifications for the sector as a whole.
|
|
Read more...
|
|
|
Product Report
|
Innovation in Drug Delivery: The future of nanotechnology and non-invasive protein delivery
Innovation in Drug Delivery provides an in-depth examination of product launches and pipeline drugs with novel drug delivery mechanisms set to revolutionize the market, such as products using ALZA Corporation’s E-TRANS and Altea’s PassPort patch transdermal technologies.
|
|
Read more...
|
|
|
Product Report
|
Next-Generation Nutraceuticals: Food and pharma convergence
Next-Generation Nutraceuticals is a new report published by Business Insights that provides analysis of how the food and pharmaceutical industries are becoming more aligned in their approach to consumer health.
|
|
Read more...
|
|
|
Company Report
|
Biopartnering Strategies: Maximizing returns from biotechnology deal-making
Biopartnering Strategies is a unique report from the Drug Discovery series that provides an essential guide to the biopartnering process, for both in-licensing and out-licensing companies.
|
|
Read more...
|
|
|
Product Report
|
Innovations in CNS: Novel therapeutics and future RandD strategies
The CNS drug market presents significant profit opportunities, but also carries high risks for companies aiming to achieve blockbuster status.
|
|
Read more...
|
|
|
Market Report
|
The Cardiovascular Market Outlook to 2011
The Cardiovascular Market Outlook to 2011 is a new report from Business Insights providing analysis of the current and future market for cardiovascular drugs across all major indications. Forecasts are given based on new product launches, upcoming patent expiry dates, and ongoing clinical trials to enable you to predict changes in the dynamics of the global cardiovascular market.
|
|
Read more...
|
|
|
Market Report
|
Innovations in Cancer: Novel therapeutics, new diagnostics and future RandD strategies
The cancer market is highly dynamic, creating a new age of discovery and innovation driven by molecular biology, oncogenomics and new methods in cell biology.
|
|
Read more...
|
|
|
Product Report
|
Next Generation Protein Engineering & Drug Design: Strategies to boost efficacy
The success of protein and peptide therapeutics is revolutionizing the biotech and pharmaceutical market, spurring the creation of next-generation products with reduced immunogenicity, improved safety and greater effectiveness.
|
|
Read more...
|
|
|
Market Report
|
The Dermatology Market Outlook to 2011
The Dermatology Market Outlook to 2011 provides detailed analysis on 5 indications within the dermatology market, identifying high growth brands, future market leaders and key drug classes.
|
|
Read more...
|
|
|
Market Report
|
eHealth Solutions for Pharma: Strategies for salesforces, marketing and patient compliance
The online channel offers a key opportunity for pharma companies to restructure their sales and marketing model, improving their relationships with physicians and increasing compliance among patients.
|
|
Read more...
|
|
|
Company Report
|
Indication Expansion: Opportunities for successful lifecycle management
Due to shrinking pipelines and rising financial pressures on pharmaceutical companies, indication expansion is an increasingly attractive strategy to expand patient potential and extend market exclusivity.
|
|
Read more...
|
|
|
Product Report
|
Winning Product Launch Strategies: Maximizing sales from new pharmaceutical products
With pharmaceutical R&D continuing to suffer from declining productivity levels and stagnant returns on investment, effective, flexible and commercially successful new product launches have become more important than ever.
|
|
Read more...
|
|
Farmavita.Net Journal 
